Armistice Capital’s Amryt Pharma AMYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-978,000
Closed -$7.14M – 267
2022
Q4
$7.14M Sell
978,000
-294,000
-23% -$2.07M 0.12% 87
2022
Q3
$8.8M Buy
1,272,000
+94,000
+8% +$701K 0.15% 77
2022
Q2
$8.23M Buy
1,178,000
+178,000
+18% +$1.39M 0.14% 86
2022
Q1
$8.27M Buy
1,000,000
+200,000
+25% +$1.8M 0.16% 79
2021
Q4
$8.64M Buy
800,000
+176,000
+28% +$1.9M 0.14% 98
2021
Q3
$7.52M Buy
624,000
+288,000
+86% +$3.25M 0.13% 97
2021
Q2
$4.08M Buy
336,000
+136,000
+68% +$1.69M 0.07% 98
2021
Q1
$2.79M Hold
200,000
– – 0.06% 96
2020
Q4
$2.83M Sell
200,000
-106,000
-35% -$1.38M 0.1% 90
2020
Q3
$3.78M Buy
+306,000
New +$3.54M 0.14% 83

Other funds holding AMYT

Armistice Capital's AMYT Position: Q1 2023 in Review

Armistice Capital sold out of Amryt Pharma (AMYT) in Q1 2023, closing a stake of 978,000 shares — an estimated $7.14M sold.

Armistice Capital first reported a position in AMYT in Q3 2020 and held it in 10 quarters. The position peaked at $8.8M in Q3 2022. 79 funds tracked by Wall St. Rank hold AMYT as of Q1 2023.

  • Armistice Capital reported no remaining Amryt Pharma position as of Q1 2023 after selling out during the quarter.
  • Armistice Capital sold 978,000 Amryt Pharma shares in Q1 2023, an estimated $7.14M.
  • Armistice Capital first reported a position in Amryt Pharma in Q3 2020 and held it in 10 quarters.
  • Armistice Capital's Amryt Pharma position peaked at $8.8M in Q3 2022.
  • 79 funds tracked by Wall St. Rank held Amryt Pharma as of Q1 2023.

Based on Armistice Capital's 13F filing for Q1 2023, filed 15 May 2023.